A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to identify biomarkers which may predict improvement in progression
free survival from treatment with Tarceva, in patients with advanced pancreatic cancer who
failed one prior regimen of standard chemotherapy or who are deemed unsuitable for
chemotherapy. It will also assess the efficacy and safety of Tarceva in this patient
population. Patients will be randomized to receive either Tarceva 150mg/day po, or placebo po
daily. Tumor tissue will be used for biomarker analysis. The anticipated time on study
treatment is until disease progression, and the target sample size is 100-500 individuals.